Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers. (Q37110011)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18340507%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

review article

1 reference

title

Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18340507%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18340507%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

author name string

Takayuki Fukui

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18340507%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

publication date

14 March 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18340507%20AND%20SRC:MED&resulttype=core&format=json

General thoracic and cardiovascular surgery

4 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18340507%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

volume

56

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18340507%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18340507%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

page(s)

97-103

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18340507%20AND%20SRC:MED&resulttype=core&format=json

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

4 January 2020

cites work

1 reference

12 December 2020

Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer.

1 reference

12 December 2020

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

1 reference

12 December 2020

Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication.

1 reference

12 December 2020

Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib

1 reference

12 December 2020

Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.

1 reference

12 December 2020

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

1 reference

12 December 2020

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

1 reference

12 December 2020

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

1 reference

12 December 2020

Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization–Positive/Phospho-Akt–Positive or Never Smoker Patients With Advanced Non–Small-Cell Lung Cancer: The ONCOBELL Trial

1 reference

12 December 2020

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

12 December 2020

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

12 December 2020

Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung

1 reference

12 December 2020

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

12 December 2020

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

1 reference

12 December 2020

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

12 December 2020

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

12 December 2020

p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking

1 reference

12 December 2020

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

12 December 2020

Erlotinib in previously treated non-small-cell lung cancer

1 reference

12 December 2020

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

1 reference

12 December 2020

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

1 reference

12 December 2020

EGFR mutation and response of lung cancer to gefitinib

1 reference

12 December 2020

Biological and clinical implications of EGFR mutations in lung cancer.

1 reference

12 December 2020

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

1 reference

12 December 2020

Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation

1 reference

12 December 2020

10.1007/S11748-007-0193-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18340507%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference